Cargando…

Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses

BACKGROUND: The current standard of chemotherapy response evaluation holds the most important prognostic factor to be the histological assessment of the tumor necrosis of the excised lesion, but the major challenge is to find an early prognostic factor that will allow the adjuvant treatment regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubo, Tadahiko, Furuta, Taisuke, Sakuda, Tomohiko, Ochi, Mitsuo, Adachi, Nobuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320105/
https://www.ncbi.nlm.nih.gov/pubmed/30572434
http://dx.doi.org/10.1097/MD.0000000000013308
_version_ 1783385172117291008
author Kubo, Tadahiko
Furuta, Taisuke
Sakuda, Tomohiko
Ochi, Mitsuo
Adachi, Nobuo
author_facet Kubo, Tadahiko
Furuta, Taisuke
Sakuda, Tomohiko
Ochi, Mitsuo
Adachi, Nobuo
author_sort Kubo, Tadahiko
collection PubMed
description BACKGROUND: The current standard of chemotherapy response evaluation holds the most important prognostic factor to be the histological assessment of the tumor necrosis of the excised lesion, but the major challenge is to find an early prognostic factor that will allow the adjuvant treatment regimen to be adjusted. The objective of this systematic review is to provide an up-to-date and unprecedented summary of the value of (99m)Technetium-methylene diphosphate or -hydroxymethylene diphosphate ((99m)Tc-MDP/HMDP) scintigraphy for the preoperative evaluation of osteosarcoma response to chemotherapy. METHODS: Studies evaluating the alteration ratio (percentage change of the Tc-99m -MDP/HMDP uptake between before and after neoadjuvant chemotherapy) to predict the histological response of osteosarcoma to chemotherapy were searched for in MEDLINE, EMBASE, and Web of Science. A meta-analysis of individual patient data (IPD) was performed to determine the optimal cut-off point from the receiver operating characteristic (ROC) curve. Additionally, aggregate data (AD) meta-analysis was performed to compare the value of (99m)Tc-MDP/HMDP scintigraphy with that of other quantitative modalities, such as dynamic magnetic resonance imaging (MRI), (201)Tl scintigraphy, and (18)F-FDG PET-CT. RESULTS: Seven studies with 154 patients were included for the IPD meta-analysis. The optimal cut-off point of the alteration ratio was 31.0%. Five studies with 123 patients were considered for the AD meta-analysis. The pooled sensitivity and specificity were 0.76 (95% CI, 0.63–0.86) and 0.89 (95% CI, 0.79–0.95), respectively. There was a significant difference between the good and poor responders in terms of the diagnostic odds ratio. The summary ROC curve demonstrated that the area under curve (AUC) was 0.892, indicating excellent diagnostic accuracy. CONCLUSION: Our findings have suggested that conventional (99m)Tc-MDP/HMDP scintigraphy remains as useful as recent quantitative modalities to predict the histological response of osteosarcoma to neoadjuvant chemotherapy.
format Online
Article
Text
id pubmed-6320105
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63201052019-01-14 Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses Kubo, Tadahiko Furuta, Taisuke Sakuda, Tomohiko Ochi, Mitsuo Adachi, Nobuo Medicine (Baltimore) Research Article BACKGROUND: The current standard of chemotherapy response evaluation holds the most important prognostic factor to be the histological assessment of the tumor necrosis of the excised lesion, but the major challenge is to find an early prognostic factor that will allow the adjuvant treatment regimen to be adjusted. The objective of this systematic review is to provide an up-to-date and unprecedented summary of the value of (99m)Technetium-methylene diphosphate or -hydroxymethylene diphosphate ((99m)Tc-MDP/HMDP) scintigraphy for the preoperative evaluation of osteosarcoma response to chemotherapy. METHODS: Studies evaluating the alteration ratio (percentage change of the Tc-99m -MDP/HMDP uptake between before and after neoadjuvant chemotherapy) to predict the histological response of osteosarcoma to chemotherapy were searched for in MEDLINE, EMBASE, and Web of Science. A meta-analysis of individual patient data (IPD) was performed to determine the optimal cut-off point from the receiver operating characteristic (ROC) curve. Additionally, aggregate data (AD) meta-analysis was performed to compare the value of (99m)Tc-MDP/HMDP scintigraphy with that of other quantitative modalities, such as dynamic magnetic resonance imaging (MRI), (201)Tl scintigraphy, and (18)F-FDG PET-CT. RESULTS: Seven studies with 154 patients were included for the IPD meta-analysis. The optimal cut-off point of the alteration ratio was 31.0%. Five studies with 123 patients were considered for the AD meta-analysis. The pooled sensitivity and specificity were 0.76 (95% CI, 0.63–0.86) and 0.89 (95% CI, 0.79–0.95), respectively. There was a significant difference between the good and poor responders in terms of the diagnostic odds ratio. The summary ROC curve demonstrated that the area under curve (AUC) was 0.892, indicating excellent diagnostic accuracy. CONCLUSION: Our findings have suggested that conventional (99m)Tc-MDP/HMDP scintigraphy remains as useful as recent quantitative modalities to predict the histological response of osteosarcoma to neoadjuvant chemotherapy. Wolters Kluwer Health 2018-12-21 /pmc/articles/PMC6320105/ /pubmed/30572434 http://dx.doi.org/10.1097/MD.0000000000013308 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Kubo, Tadahiko
Furuta, Taisuke
Sakuda, Tomohiko
Ochi, Mitsuo
Adachi, Nobuo
Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title_full Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title_fullStr Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title_full_unstemmed Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title_short Conventional (99m)Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: Individual patient data and aggregate data meta-analyses
title_sort conventional (99m)tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy: individual patient data and aggregate data meta-analyses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320105/
https://www.ncbi.nlm.nih.gov/pubmed/30572434
http://dx.doi.org/10.1097/MD.0000000000013308
work_keys_str_mv AT kubotadahiko conventional99mtchydroxymethylenediphosphateremainsusefultopredictosteosarcomaresponsetoneoadjuvantchemotherapyindividualpatientdataandaggregatedatametaanalyses
AT furutataisuke conventional99mtchydroxymethylenediphosphateremainsusefultopredictosteosarcomaresponsetoneoadjuvantchemotherapyindividualpatientdataandaggregatedatametaanalyses
AT sakudatomohiko conventional99mtchydroxymethylenediphosphateremainsusefultopredictosteosarcomaresponsetoneoadjuvantchemotherapyindividualpatientdataandaggregatedatametaanalyses
AT ochimitsuo conventional99mtchydroxymethylenediphosphateremainsusefultopredictosteosarcomaresponsetoneoadjuvantchemotherapyindividualpatientdataandaggregatedatametaanalyses
AT adachinobuo conventional99mtchydroxymethylenediphosphateremainsusefultopredictosteosarcomaresponsetoneoadjuvantchemotherapyindividualpatientdataandaggregatedatametaanalyses